In addition, MFC could detect a potential target for immunotherapeutic approaches on the surface of the malignant PC (SLAMF7, CD52, CD30, CD38, CD22, and CD20) in approximately all patients. This evidence concerns the gene TNFRSF8 and pachyonychia congenita.